A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Generation of GABAergic Neurons from Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible ASCL1/DLX2 Expression at AAVS1

111 views

⸱

DOI:

10.3791/71804

⸱

July 31st, 2026

 , 

* These authors contributed equally

In This Article

Summary

This protocol describes a method for generating GABAergic neurons from human induced pluripotent stem cells by integrating doxycycline-inducible transgenes into the AAVS1. safe harbor locus. The stable, homogeneous transgene expression provides an efficient approach for direct differentiation into GABAergic neurons while limiting transgene silencing, a common issue with lentiviral approaches.

Abstract

Human induced pluripotent stem cells (hiPSCs) offer an unprecedented opportunity to model human neurological diseases in vitro. Reliable generation of defined neuronal populations, such as gamma-aminobutyric acid (GABAergic) neurons, is essential for these studies. This protocol details a robust method for differentiating hiPSCs into GABAergic neurons using a doxycycline-inducible system. The approach relies on the stable integration of transgenes encoding the transcription factors ASCL1 and DLX2 into the safe-harbor adeno-associated virus integration site 1 (AAVS1.) locus via CRISPR/Cas9-mediated knock-in. This targeted integration avoids the transgene silencing often observed with random lentiviral integration. The protocol covers the maintenance of hiPSCs, the nucleofection process for transgene integration, puromycin selection to enrich successfully engineered cells, and the step-by-step differentiation procedure. Upon induction with doxycycline, the engineered hiPSCs rapidly exit the cell cycle, acquire neuronal morphology, and express GABAergic lineage markers within 21 days. Key steps include neuro-induction and subsequent maturation using specific growth factors, as well as potential approaches to improve cellular adhesion during maturation. This standardized method yields enriched populations of induced neurons expressing GABAergic lineage markers, providing a valuable tool for neuroscience research and cellular modeling.

Introduction

Human induced pluripotent stem cells (hiPSCs) provide a unique platform to model human neurological diseases in vitro. and to investigate the complex molecular mechanisms that drive development and degeneration1. This technology enables the generation of patient-specific cellular models to investigate a wide array of conditions, ranging from early neurodevelopmental anomalies in syndromic ciliopathies2 to subtle epigenomic alterations observed in sporadic Alzheimer's disease3. Consequently, directed differentiation of hiPSCs has become a cornerstone of modern molecular neuroscience.

Access restricted. Please log in or start a trial to view this content.

Protocol

CAUTION: Human hiPSC cultures should be handled as potentially biohazardous material under institutional biosafety procedures. Perform all human hiPSC culture procedures in a certified Class II biological safety cabinet using sterile technique. All waste containing human cells, media exposed to human cells, and CRISPR/Cas9 plasmid material should be decontaminated in accordance with local biosafety guidelines before disposal. Doxycycline, puromycin, DMSO, and other chemical reagents should be handled with gloves and appropriate eye and skin protection, and waste should be discarded according to institutional chemical-waste procedures. Basement membrane extract (BME) s....

Access restricted. Please log in or start a trial to view this content.

Results

Successful application of this protocol results in an enriched population of induced neurons with GABAergic molecular features. The strategy is based on targeted insertion of a doxycycline-inducible ASCL1-P2A-DLX2 cassette into the AAVS1 locus (Figure 1A). Following selection of engineered hiPSCs, doxycycline induction is used to drive GABAergic neuronal differentiation, as outlined in the timeline shown in Figure 1B. Following nucleof.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The successful generation of GABAergic neurons relies heavily on several critical steps within this protocol. Maintaining high-quality, undifferentiated hiPSCs is paramount; spontaneous differentiation prior to nucleofection drastically reduces integration efficiency and downstream neuronal purity8. Furthermore, precise determination of the puromycin kill curve is essential to ensure complete elimination of non-integrated cells without undue stress on properly engineered clones. During the differe.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare no competing financial interests.

Acknowledgements

Support was provided by the Canadian Stem Cell Network Jump Start ECR Program and the Fonds UdeM pour le partenariat CHU Sainte-Justine -Institut Imagine en épilepsie de l’enfant. Théo Rabin is supported by the Odisé network.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
4D-Nucleofector™ Core UnitLonzaAAF-1002BFor electroporation/nucleofection of hiPSCs.
6-well culture platesSarstedt83.3920300Tissue culture-treated plates for hiPSC maintenance and differentiation.
BDNF (Brain-Derived Neurotrophic Factor)STEMCELL Technologies78005Recombinant human protein for neuronal maturation; prepare according to manufacturer instructions and use at 10 ng/mL final concentration.
Cell counter (Countess)Thermo Fisher ScientificC10283Used for cell counting.
CentrifugeVWR76468-134For cell pelleting.
CO2 incubatorThermo Fisher ScientificHeracell VIOS 160i or equivalentCell culture incubator maintaining 37 °C, humidified atmosphere, and 5% CO2.
CryotubesThermo Fisher Scientific5000-0020Sterile cryogenic vials for freezing hiPSCs; equivalent externally threaded 1.8–2.0 mL cryovials may be used.
Cultrex UltiMatrix Reduced Growth Factor Basement Membrane ExtractBio-TechneBME001-05Standard BME coating matrix used in the protocol. Verify the lot-specific stock concentration from the Bio-Techne certificate of analysis and dilute in DMEM/F-12 to 80 µg/mL working concentration.
DMEM/F-12Wisent319-090-CLBasal medium used for diluting BME.
DMSO (Dimethyl sulfoxide)Sigma-AldrichD2650Cryoprotectant used in the preparation of freezing medium.
Donor plasmid: inducible ASCL1-P2A-DLX2 AAVS1 targeting cassetteCustom plasmidAddgene accession pendingCustom AAVS1 donor plasmid containing doxycycline-inducible ASCL1-P2A-DLX2 cassette and selection/reporter elements. Provide plasmid map and full sequence as supplementary file or upon request.
Doxycycline hyclateSigma-AldrichD9891Used to induce ASCL1-P2A-DLX2 expression. Prepare sterile stock solution, aliquot, protect from light, store frozen, and use at 1 µg/mL final concentration.
Ethanol (70%)Commercial Alcohols / Greenfield GlobalP016EAANFor sterilization inside the biological safety cabinet; use institutional approved 70% ethanol or equivalent.
Fluorescence microscopeECHORevolve R4Microscope used for phase-contrast and fluorescence imaging of reporter expression and neuronal morphology.
GDNF (Glial-Derived Neurotrophic Factor)STEMCELL Technologies78058Recombinant human protein for neuronal maturation; prepare according to manufacturer instructions and use at 10 ng/mL final concentration.
hiPSC line PGP1EditCo BioPGP1 human iPSC lineCommercially available open-consent human iPSC line used in this protocol; record passage number and QC status before editing and differentiation.
Image-analysis softwareImageJ/FijiOpen-source; version used should be reportedFor fluorescence quantification and representative image processing.
KnockOut™ Serum Replacement (KOSR)Thermo Fisher Scientific10828028Used in the preparation of freezing medium.
Laminin-521STEMCELL Technologies200-0117Optional troubleshooting reagent only. Not part of the standard coating protocol; may be used as an alternative or double-coating matrix if neuronal detachment persists.
Liquid nitrogen dewarThermo Fisher ScientificLocator 6 Plus or equivalentLong-term storage of frozen hiPSCs in vapor-phase or liquid nitrogen according to institutional cryogenic safety procedures.
Mr. Frosty™ Freezing ContainerThermo Fisher Scientific5100-0001For controlled-rate freezing of cells at -80 °C.
mTeSR™ PlusSTEMCELL Technologies100-0276Feeder-free maintenance medium for hiPSCs.
Neuro-induction mediumSTEMCELL Technologies08582Commercial neuro-induction medium used for early neuronal induction.
Neuro-maturation base medium (BrainPhys™ Neuronal Medium)STEMCELL Technologies05790Base medium for neuronal maturation; supplement with BDNF, GDNF, NT-3, doxycycline, and PluriSln-1 as described in the protocol.
NT-3 (Neurotrophic Factor 3)STEMCELL Technologies78074Recombinant human protein for neuronal maturation; prepare according to manufacturer instructions and use at 10 ng/mL final concentration.
P3 Primary Cell 4D-Nucleofector™ X KitLonzaV4XP-3024Kit containing Solution P3 and cuvettes for hiPSC nucleofection.
Penicillin-Streptomycin (10,000 U/mL)Thermo Fisher Scientific15140122Optional antibiotic to reduce bacterial contamination risk.
Plasmocin™ prophylacticInvivoGenant-mppOptional antibiotic to prevent mycoplasma contamination.
PluriSIn-1STEMCELL Technologies72822Pluripotent cell survival inhibitor to eliminate undifferentiated hiPSCs; prepare stock according to manufacturer instructions and use at 20 µM final concentration.
Puromycin DihydrochlorideThermo Fisher ScientificA1113803Antibiotic used for selection; prepare sterile stock solution, aliquot, store frozen, and determine final working concentration by kill curve, typically 0.4–0.6 µg/mL.
pX330-U6-Chimeric_BB-CBh-hSpCas9 AAVS1 gRNA plasmidAddgene85802CRISPR/Cas9 plasmid used for AAVS1 targeting; include the AAVS1 gRNA sequence in the plasmid map or supplementary information.
qPCR analysis softwareApplied Biosystems / Thermo Fisher ScientificQuantStudio Design & Analysis Software or equivalentFor Ct extraction and RT-qPCR analysis; report software version used.
qPCR master mixThermo Fisher ScientificPowerUp SYBR Green Master Mix, A25742For RT-qPCR quantification of neuronal and GABAergic markers.
qPCR primers: DLX1Custom oligonucleotidesSequence provided in commentsForward: 5' ATGCACTGTTTACACTCGGC 3'; Reverse: 5' GACTGCACCGAACTGATGTAG 3'. Used to assess GABAergic lineage induction at Day 21.
qPCR primers: GAD2Custom oligonucleotidesSequence provided in commentsForward: 5' TGGCGTTTCTGCAAGATGTTA 3'; Reverse:5' TTGGTCTGCCAATTCCCAATTAT 3'. GABAergic neuron marker.
qPCR primers: GAD67Custom oligonucleotidesSequence provided in commentsForward: 5' GCTTCCGGCTAAGAACGGT 3'; Reverse: 5' TTGCGGACATAGTTGAGGAGT 3'. GABAergic neuron marker.
qPCR primers: RPLP0Custom oligonucleotidesSequence to be providedReference gene primers for ΔΔCt normalization. Primer sequences should be listed in the table or supplementary information. Forward: 5' AGCCCAGAACACTGGTCTC 3'; Reverse: 5' ACTCAGGATTTCAATGGTGCC 3'.
qPCR primers: SLC17A6Custom oligonucleotidesSequence provided in commentsForward: 5' GGGAGACAATCGAGCTGACG 3'; Reverse: 5'TGCAGCGGATACCGAAGGA3'. Glutamatergic neuron marker.
qPCR primers: SLC17A7Custom oligonucleotidesSequence provided in commentsForward: 5' CAGAGTTTTCGGCTTTGCTATTG 3'; Reverse: 5' GCGACTCCGTTCTAAGGGTG 3'. Glutamatergic neuron marker.
ReLeSR™STEMCELL Technologies100-0484Enzyme-free reagent for dissociation and passaging of hiPSCs.
Reverse-transcription kitThermo Fisher ScientificSuperScript IV VILO Master Mix, 11756050For cDNA synthesis prior to RT-qPCR.
RNA extraction kitQIAGENRNeasy Kit (74104)Kit used for total RNA extraction before RT-qPCR. Record the exact RNeasy kit format and catalog number used in the final Materials table.
Statistical softwareGraphPad SoftwareGraphPad Prism, version 11For graphing and statistical analysis of RT-qPCR data.
Trypan Blue Solution (0.4%)Thermo Fisher Scientific15250061Vital stain used to assess cell viability during counting.
Y-27632 (ROCK Inhibitor)STEMCELL Technologies72302Used at 10 µM final concentration to improve survival during passaging and nucleofection.

References

  1. Mertens J, Marchetto MC, Bardy C, Gage FH. Evaluating cell reprogramming, differentiation, and conversion technologies in neuroscience. Nat Rev Neurosci. 2016 Jul;17(7):424-37.
  2. Barabino A, Flamier A, Hanna R, Héon E, Freedman BS, Bernier G. Deregulation of Neuro-Developmental Genes and Primary Cilium Cytoskeleton Anomalies in iPSC Retinal Sheets from Human Syndromic Ciliopathies. Stem Cell Reports. 2020 Mar 10;14(3):357-73.
  3. Katbe A, Hanna R, Flamier A, Serhani D, Hamam R, Barabino A, et al. Epigenomic alterations and neural development anomalies in induced pluripotent stem cells from sporadic Alzheimer’s disease. Development. 2026 Jan 1;153(1):dev2049....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Doxycycline-Inducible ExpressionAAVS1 LocusCRISPR Knock-InNeuronal DifferentiationPuromycin SelectionNeuro-InductionNeuronal Maturation

This article has been published

Video Coming Soon